Atherosclerotic coronary artery disease (CAD) is the leading cause of death in both developed and developing 65 countries worldwide, and current estimates predict that more than 1 million individuals will suffer from new and 66 recurrent CAD this year in the U.S. alone 1 . Like most polygenic diseases, both genetic and environmental 67 factors influence an individual's lifetime risk for CAD 2 . Early Swedish twin studies and more recent genome-68 wide association studies (GWAS) have estimated that about 50% of CAD risk is explained by genetic factors 3, 4 . 69
To date, GWAS have reported more than 95 replicated independent loci and numerous additional loci that are 70 associated at an FDR<0.05 [5] [6] [7] [8] . A majority of these loci reside in non-coding genomic regions and are expected 71 to function through regulatory mechanisms. Also, approximately 75% of CAD loci are not associated with 72 classical risk factors, suggesting that at least part of them function through mechanisms intrinsic to the vessel 73 wall. 74 75 were cultured in smooth muscle growth medium (Lonza catalog # CC-3182) supplemented with hEGF, insulin, 04 hFGF-b, and 5% FBS, according to Lonza instructions. All HCASMC lines were expanded to passage 5-6 prior 05 to extraction. 06 07 Library preparation and sequencing. Whole Genome Sequencing: Genomic DNA was isolated using Qiagen 08 DNeasy Blood & Tissue Kit (catalog # 69506) and quantified using NanoDrop 1000 Spectrophotometer 09 (Thermo Fisher). Macrogen performed library preparation using Illumina's TruSeq DNA PCR-Free Library 10 Preparation Kit and 150 bp paired-end sequencing on Illumina HiSeq X Ten System. RNA Sequencing: RNA 11 was extracted using Qiagen miRNeasy Mini Prep Kit (catalog # 74106). Quality of RNA was assessed on the 12 Agilent 2100 Bioanalyzer. Samples with RIN greater than or equal to 8 were sent to the Next-Generation 13
Sequencing Core at the Perelman School of Medicine at the University of Pennsylvania. Libraries were made 14 using Illumina TruSeq Stranded Total RNA Library Prep Kit (catalog # 20020597) and sequenced using 125bp 15 paired-end on HiSeq 2500 Platform. ATAC Sequencing: We used ATAC-seq to assess chromatin accessibility 16 with slight modifications to the published protocol 57 . Approximately 5x10 4 fresh cells were collected at 500 g, 17 washed in PBS, and nuclei extracted with cold lysis buffer. Pellets were subjected to transposition containing 18 Tn5 transposases (Illumina) at 37 °C for 30 min, followed by purification using the DNA Clean-up and 19 Concentration kit (Zymo). Libraries were PCR amplified using Nextera barcodes, with the total number of 20 cycles empirically determined using SYBR qPCR. Amplified libraries were purified and quantified using 21 bioanalyzer, nanodrop and qPCR (KAPA) analysis. Libraries were multiplexed and 2x75 bp sequencing was 22 performed using an Illumina NextSeq 500. 23 24 Alignment and quantification of genomic, transcriptomic and epigenomic features. Whole-genome 25 sequencing data were processed with the GATK best practices pipeline with hg19 as the reference 26 genome 20,58 , and VCF records were phased with Beagle v4.1 59 . Variants with imputation allelic r 2 less than 0.8 27 and Hardy-Weinberg Equilibrium p-value less than 1x10 -6 were filtered out (see Supplementary Note). multiplexed FASTQ files were mapped with STAR version 2.4.0i in 2-pass mode 60 over the hg19 reference 29 genome. Prior to expression quantification, we filtered our reads prone to mapping bias using WASP 61 . Total 30 read counts and RPKM were calculated with RNA-SeQC v1.1.8 62 using default parameters with additional flags 31 determined by empirically maximize the power to discover eQTLs on chromosome 20 (for computational speed 48 and to avoid overfitting). We tested combinations of 3 to 5 genotype principal components with 1 to 15 PEER 49 factors. We found that the combination of 4 genotype PCs with 8 PEER factors provides the most power to 50 detect eQTLs. We then used sex, the top four genotype principal components, and the top eight PEER factors 51 in both FastQTL and RASQUAL to map cis-eQTL with a 2Mb window centered at transcription start sites. 52 Mathematically, the model is the following: 53
Colocalization between molecular QTL and CAD genome-wide association study (GWAS). We used 86 summary-data-based Mendelian Randomization (SMR) 37 to determine GWAS loci that can be explained by cis-87 acting QTLs. We performed colocalization tests for 3,379 genes with cis-eQTL p-value < 5x10 -5 for the top 88 variant and 2,439 splicing events with cis-sQTL p-value < 5x10 -5 for the top variant in HCASMC against the 89 latest CARDIoGRAMplusC4D and UK Biobank GWAS meta-analysis 6 . We identified genome-wide significant 90 eQTL and sQTL colocalizations based on adjusted SMR p-values (Benjamini-Hochberg FDR < 0.05). The 91 equivalent p-value was 2.96x10 -5 and 2.05x10 -5 for eQTL and sQTL, respectively. SMR uses a reference 92 population to determine linkage between variants; we used genetic data from individuals of European ancestry 93 from 1000 Genomes as the reference population in our analyses. We also used a modified version of 94 eCAVIAR 35 to identify colocalized signals (see Supplementary Note). We calculated colocalization posterior 95 probability (CLPP) using all SNPs within 500kb of the lead eQTL SNP against CAD summary statistics from 96
CARDIoGRAMplusC4D and UK Biobank GWAS meta-analysis 6 . For computational feasibility, the GWAS and 97 eQTL loci were assumed to have exactly one causal SNP. We defined colocalization events using CLPP > 98 0.05. Note that this is more conservative than the default eCAVIAR cutoff (CLPP > 0.01). We determined the 99 direction of effect, namely whether gene upregulation increases risk, using the correlation of effect sizes in the 00 GWAS and the eQTL studies. We selected SNPs with p-value < 1x10 -3 in both the GWAS and eQTL datasets 01 (since other SNPs carry mostly noise), and fitted a regression using the GWAS and eQTL effect sizes as the 02 predictor and the response, respectively. We defined the direction of effect as the sign of the regression slope. 03
04

Results
05
HCASMC-specific genomic architecture 06
We obtained and cultured 62 primary HCASMC lines, and 52 lines remained for analysis after stringent quality 07 control (Supplementary Note and Table S1 ). We performed whole-genome sequencing to an average depth 08 of 30X, and jointly called genotypes using the GATK best practices pipeline 20 , producing a total of ~15.2 million 09 variants after quality control (see Methods). For RNA, we performed 125bp paired-end sequencing to a 10 median depth of 51.3 million reads, with over 2.7 billion reads in total. After quantification and quality control, 11 19,607 genes were expressed in sufficient depth for downstream analysis (Table 1) . To confirm that HCASMC 12 derived from tissue culture reflect in vivo physiology, we first projected their transcriptomes onto the 53 tissues 13 profiled in GTEx 19 (Fig. 1A ). Using multi-dimensional scaling (MDS) to visualize the similarity of HCASMC to 14 GTEx tissues, we observed that HCASMC forms a distinct cluster and closely neighbors fibroblasts, skeletal 15 muscle, arteries, heart and various smooth muscle-enriched tissues (vagina, colon, stomach, uterus and 16 esophagus). These results were expected given that HCASMC are predicted to be similar to skeletal muscle, 17 smooth muscle-enriched tissues as well as tissues representing the same anatomical compartment (e.g. heart 18 and artery) 21 . In addition, HCASMC resemble fibroblast as both can be differentiated from mesenchymal cells 19 from the dorsal mesocardium 22 . We also computed the epigenetic similarity between HCASMC and ENCODE 20 cell types 23 . Consistent with the transcriptomic findings, the closest neighbors to HCASMC using epigenomic 21 data were fibroblasts, heart, lung and skeletal muscle ( Fig. 1B) . 22
23
Next, we determined the pathways that may be selectively upregulated in HCASMC compared to closely 24 related tissues. We performed differential expression analysis of HCASMC against fibroblasts and coronary 25 artery in GTEx after correcting for batch effects and other hidden confounders (see Methods). Overall, 2,610 26 and 6,864 genes were found to be differentially expressed, respectively (FDR < 1x10 -3 , Fig. 1C and Fig. S1 ), 27 affecting pathways involved in cellular proliferation, epithelial-mesenchymal transition (EMT) and extracellular 28 matrix (ECM) secretion (Table S2 ). Next, we sought to identify HCASMC-specific epigenomic signatures by 29 comparing HCASMC open chromatin profiles, as determined with ATAC-seq, against DNaseI hypersensitivity 30 (DHS) sites across all ENCODE primary cell types and tissues (Table S3 ). We processed HCASMC ATAC-seq 31 data with the ENCODE pipeline and standardized peaks as 75 bp around the peak summit for all tissues and 32 cell lines to mitigate batch effect (see Methods). A total of 7332 peaks (2.1%) were not previously identified in 33 ENCODE and represent HCASMC-specific sites ( Fig. 1D ). For example, an intronic peak within the LMOD1 34 gene was found to be unique to HCASMC (Fig. 1E ). This gene is expressed only in vascular and visceral 35 smooth muscle cells where it is involved in actin polymerization, and has been mapped as a candidate causal 36 CAD gene 11 . We then sought to identify transcription factor binding sites overrepresented in HCASMC-specific 37 peaks. Motif enrichment analyses indicated that HCASMC-specific open chromatin sites are enriched with 38 binding sites for members of the forkhead box (FOX) transcription factor family (see Methods). We performed 39 motif enrichment analysis using 50-, 200-, and 1000-bp regions flanking HCASMC-specific peaks, and found 40 that the enrichment was robust to selection of window size, indicating the result is not simply due to selection 41 bias ( Fig. S2 ). The FOX transcription factors are known to regulate tissue-and cell-type specific gene 42 transcription 24 , and a subgroup of this family includes those with the ability to serve as pioneer factors 25 . To 43 validate that FOX motif enrichment is specific to HCASMC, we performed similar analyses for brain-, heart-, 44 and fibroblast-specific open chromatin regions and observed a depletion of FOX motifs (Fig. S3 ). Together 45 these results suggest that HCASMC-specific transcriptomic and epigenomic profiles provide new regulatory 46 mechanisms previously lacking in large publicly available datasets. 47 48
Expression and splicing quantitative trait locus discovery 49
In order to investigate the genetic regulatory mechanisms of gene expression in HCASMC, we conducted 50 genome-wide mapping of eQTLs using both FastQTL 26 and RASQUAL 27 on the 52 donor samples from diverse 51 ethnic backgrounds (Table S1 and Fig S4) . RASQUAL has been previously shown to increase the cis-eQTL 52 discovery power in small sample sizes by leveraging allele-specific information 27 . Indeed, using a threshold of 53 FDR < 0.05, RASQUAL increased the number of eQTLs discovered approximately seven-fold as compared to 54 FastQTL (RASQUAL:1220 vs. FastQTL:167, Table 1 ). We next evaluated whether these eQTLs were enriched 55
in regions of open chromatin using data from a subset of individuals with ATAC-seq profiles. We observed that 56
eQTLs within HCASMC open chromatin regions had more significant p-values compared to all eQTLs ( Fig. S5 , 57 two-sided rank-sum test p-value < 9.2x10 -5 ). This is consistent with putative effects of cis-acting variation, 58 potentially functioning through altered TF binding around these accessible regions. Next, using a Bayesian 59 meta-analytic approach 28 , we sought to identify HCASMC-specific eQTLs using GTEx tissues as a reference. 60
Under the most stringent criteria (eQTL posterior probability > 0.9 for HCASMC and < 0.1 for all GTEx tissues, 61 see Methods), we identified four HCASMC-specific eQTLs ( Fig. S6 ). For example, rs1048709 is the top eQTL-62 SNP and confers HCASMC-specific regulatory effects on Complement Factor B (Fig. S6B ), a gene that has 63 been previously implicated in atherosclerosis and other inflammatory diseases 29 . In addition to regulatory 64 effects on gene expression, previous studies have identified splicing as a major source of regulatory impact of 65 genetic variation on complex diseases 30 . Therefore, we mapped splicing QTLs (sQTLs) using LeafCutter 31 and 66 identified 581 sQTLs associated at FDR < 0.05 ( Table 1) . As a quality control, we estimated the enrichment of 67 sQTLs and eQTLs against a matched set of background variants. As expected, eQTLs were enriched around 68 the 5' UTR ( Fig. S7A ), whereas sQTLs were enriched in splicing regions, particularly splice donor and acceptor 69 sites ( Fig. S7B ). 70
71
Overall CAD genetic risk mediated by HCASMC 72
We next examined the heritable contribution of HCASMC towards the risk of CAD. Previous reports have 73 suggested that disease-associated SNPs are often enriched in genes expressed in the relevant tissue types 32 . 74
Thus, we estimated the contribution to CAD risk from SNPs in or near genes showing patterns of tissue-75 specific expression and identified the top 2000 tissue-specific genes for HCASMC and GTEx tissues (see 76 Methods). We then applied stratified LD score regression 33 to estimate CAD heritability explained by SNPs 77 within 1kb of tissue-specific genes. We found that HCASMC, along with coronary artery and adipose tissues, 78 contribute substantially towards CAD heritability ( Fig. 2A ). These enrichment results were robust to the tissue-79 specificity cutoff (top 1000, 2000, or 4000 genes), suggesting that they were not simply due to selection bias 80 
Fine-mapping CAD risk variants 89
Whole-genome sequencing of our HCASMC population sample provides the opportunity to fine-map CAD risk 90 loci. Several studies have used colocalization between GWAS and eQTL signals as a fine-mapping approach 91 to identify candidate causal regulatory variants [35] [36] [37] [38] , and in several cases pinpointing single causal variants 39,40 . 92 Given the global overlap between CAD risk variants and genetic regulation in HCASMC, we sought to find 93 evidence for colocalization between GWAS and eQTL signals. We thus compiled publicly available genome-94 wide summary statistics from the latest meta-analysis 6 . We then applied two methods with different statistical 95 assumptions, eQTL and GWAS CAusal Variants Identification in Associated Regions (eCAVIAR) 35 and 96 Summary-data-based Mendelian Randomization (SMR) 37 to identify colocalizing variants and genes across all 97 CAD loci, and focused on the union of results from the two independent methods. We used FDR < 0.05 and 98 colocalization posterior probability (CLPP) > 0.05 as cutoffs for SMR and eCAVIAR, respectively (Note that 99 CLPP > 0.05 is more conservative than the CLPP > 0.01 recommended in the publication of the eCAVIAR 00 method). From this approach, we identified five high-confidence genes, namely FES, SMAD3, TCF21, 01
PDGFRA and SIPA1 (Fig. 3) . Although the top genes found by two methods differed, we observed that the 02 SMR p-values and eCAVIAR CLPPs positively correlate (Fig. S9 ), and that two of the three genes found only 03 by eCAVIAR achieved nominal significance in SMR (Table S4 ). We then investigated whether these 04 colocalizations were unique to HCASMC by conducting colocalization tests across all GTEx tissues. For SIPA1 05 and PDGFRA, colocalization appears to be HCASMC-specific ( Fig. 3G ; Fig. S10A and S10D). For SMAD3, 06 both HCASMC and thyroid have strong colocalization signals ( Fig. S10B ). TCF21 and FES colocalization were 07 found to be shared across multiple tissues ( Fig. S10C and Fig. S11D ). Next, we conducted colocalization 08 analysis between sQTL and GWAS summary statistics with both eCAVIAR and SMR. We identified 09 colocalization with four genes (Table S4 , and Fig. S12 ). The most significant colocalization event is at the 10 SMG9 locus. Interestingly, the top sQTL variant, rs4760, is a coding variant located in the exon of the PLAUR 11 (plasminogen activator urokinase receptor) gene and is also a GWAS variant for circulating cytokines and 12 multiple immune cell traits 41,42 . By correlating eQTL and GWAS effect sizes, we observed that increased 13 TCF21 and FES expression levels are associated with reduced CAD risk, while increased PDGFRA, SIPA1, 14 and SMAD3 expression levels are associated with increased CAD risk ( Fig. 4A -E). These results provide 15 genetic evidence that pathways promoting SMC phenotypic transition during atherosclerosis can be both 16 protective and detrimental depending on the genes implicated ( Fig. 4F) . 17
19
Discussion 20
In this study, we have integrated genomic, transcriptomic, and epigenetic datasets to create the first map of 21 genetic regulation of gene expression in human coronary artery smooth muscle cells. Comparison with publicly 22 available transcriptomic and epigenomic datasets in GTEx and ENCODE revealed regulatory patterns specific 23 to HCASMC. By comparing against neighboring tissues in GTEx, we found thousands of differentially 24 expressed genes, which were enriched in pathways such as EMT, protein secretion and cellular proliferation, 25 consistent with our current understanding of HCASMC physiology in vivo. In comparison with ENCODE, we 26 found 7332 (~2.1%) open chromatin peaks unique to HCASMC, and showed that these peaks are enriched 27 with binding motifs for Forkhead box family proteins, which are known to regulate cell-type-specific gene 28 expression 43 . FOXP1 in particular has been shown to increase collagen production in smooth muscle cells 44 , 29 supporting a potential role in extracellular matrix remodeling in the vessel wall. 30 31 Using both transcriptomic and epigenomic profiles, we established that HCASMC represent an important cell 32 type for coronary artery disease. On a tissue-level, we demonstrated that genes highly expressed in HCASMC, 33 coronary artery and adipose tissue are enriched for SNPs associated with CAD risk. While the proximal aortic 34 wall is also susceptible to atherosclerosis, the coronary arteries represent the primary origin of ischemic 35 coronary artery disease in humans 9 . Given that the majority of coronary arteries in the epicardium are 36 encapsulated by perivascular adipose tissue in individuals with disease, one would expect these tissues to 37 share gene responses involved in both vascular inflammation and lipid homeostasis 45 for PDGFRB mediated signaling has been well documented in atherosclerosis and modulation of SMC 50 phenotype, the possible involvement of PDGFRA has not been investigated in detail 50, 51 . Interestingly, FES 51 and SIPA1 were found to harbor CpGs identified in current smokers in the Rotterdam Study, based on targeted 52 methylation profiling of CAD loci in whole blood 52 . The two identified CpGs in FES were located near the 53 transcription start site, while the one CpG identified in SIPA1 was located in the 5'-UTR, suggesting potential 54 environmental influences on gene expression levels. SIPA1 encodes a mitogen induced GTPase activating 55 protein (GAP), specifically activating Ras and Rap GTPases 53 . SIPA1 may be a unique mitogen response 56 signal in HCASMC undergoing phenotypic transition in the injured vessel wall; however, these hypotheses 57 should be explored in relevant functional models. Another HCASMC eQTL variant, rs2327429, located in the 58 TCF21 promoter region, was also the lead SNP in this locus in a recent CAD meta-analysis and has been 59 identified as an mQTL for TCF21 expression in two separate studies 54, 55 . These data suggest that regulation of 60 methylation is a novel molecular trait that may mediate risk for CAD. Splicing QTL colocalization analysis 61 reveals that alternative splicing in SMG9 also influences CAD risk. SMG9 has been shown to regulate the non-62 sense mediated decay (NMD) pathway in human cells, and has been implicated in several developmental 63 disorders such as brain malformations and congenital heart disease 56 . 64
65
In summary, the current study confirms the value of detailed genomic and genetic analyses of disease-related 66 tissues and cell types, which when analyzed in the context of publicly available data can provide deep insights 67 into the physiology of human traits and pathophysiology of complex human disease. We expect that these 68 findings will provide a rich resource for the community and prompt detailed functional investigations of 69 candidate loci for preclinical development. 
